We are live on ! Find out more
WMSA

Weiss Multi-Strategy Advisers Portfolio holdings

AUM $4.16B
1-Year Est. Return 30.77%
This Fund
S&P 500
This Quarter Est. Return
+34.99%
1 Year Est. Return
+30.77%
3 Year Est. Return
+78.91%
5 Year Est. Return
+263.81%
10 Year Est. Return
+424.97%
AUM
$3.49B
AUM Growth
+$922M
Cap. Flow
+$316M
Cap. Flow %
9.05%
Top 10 Hldgs %
13.93%
Holding
651
New
247
Increased
146
Reduced
134
Closed
123

Sector Composition

Rank Sector Weight
1 Technology 18.26%
2 Industrials 15.69%
3 Real Estate 10.41%
4 Consumer Discretionary 10.39%
5 Healthcare 8.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HRTX icon
476
Heron Therapeutics
HRTX
$93.4M
$434K 0.01%
29,500
-1,390
-4% -$22.8K
TVRD
477
Tvardi Therapeutics
TVRD
$20.1M
$430K 0.01%
698
+205
+42% +$113K
TCMD icon
478
Tactile Systems Technology
TCMD
$618M
$413K 0.01%
9,972
+342
+4% +$16K
AXSM icon
479
Axsome Therapeutics
AXSM
$11.7B
$411K 0.01%
+5,000
New +$385K
FTNT icon
480
Fortinet
FTNT
$112B
$411K 0.01%
14,960
-410,040
-96% -$10.3M
GNW icon
481
Genworth Financial
GNW
$3.86B
$395K 0.01%
+170,989
New +$538K
ALGT icon
482
Allegiant Air
ALGT
$2.57B
$382K 0.01%
+3,500
New +$320K
IMMU
483
DELISTED
Immunomedics Inc
IMMU
$378K 0.01%
+10,663
New +$312K
GRTX
484
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$371K 0.01%
52,000
+3,508
+7% +$37.2K
FIS icon
485
Fidelity National Information Services
FIS
$24.2B
$369K 0.01%
+2,753
New +$362K
RPRX icon
486
Royalty Pharma
RPRX
$26.2B
$365K 0.01%
+7,515
New +$372K
EPZM
487
DELISTED
Epizyme, Inc
EPZM
$365K 0.01%
22,725
-2,352
-9% -$41.1K
ESPR
488
DELISTED
Esperion Therapeutics
ESPR
$359K 0.01%
+7,000
New +$293K
CSII
489
DELISTED
Cardiovascular Systems, Inc.
CSII
$349K 0.01%
11,054
+1,068
+11% +$39.9K
ATO icon
490
Atmos Energy
ATO
$29.7B
$341K 0.01%
+3,420
New +$345K
MRUS
491
DELISTED
Merus
MRUS
$333K 0.01%
20,721
-3,356
-14% -$48.6K
WGO icon
492
Winnebago Industries
WGO
$900M
$333K 0.01%
+5,000
New +$255K
GM icon
493
CALL
General Motors
GM
$80.9B
$329K 0.01%
+13,000
New +$316K
DCPH
494
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$315K 0.01%
5,268
-1,142
-18% -$61.1K
DVAX
495
DELISTED
Dynavax Technologies
DVAX
$311K 0.01%
35,088
-1,600
-4% -$8.09K
GNMK
496
DELISTED
GenMark Diagnostics, Inc
GNMK
$294K 0.01%
20,000
-21,761
-52% -$221K
HOLX
497
CALL
DELISTED
Hologic
HOLX
$291K 0.01%
+5,100
New +$250K
TELA icon
498
TELA Bio
TELA
$30.3M
$285K 0.01%
+22,000
New +$289K
WFC icon
499
CALL
Wells Fargo
WFC
$254B
$282K 0.01%
+11,000
New +$301K
TCDA
500
DELISTED
Tricida, Inc. Common Stock
TCDA
$276K 0.01%
+10,049
New +$274K

Similar funds

Weiss Multi-Strategy Advisers's Q2 2020 Portfolio in Review

As of Q2 2020, Weiss Multi-Strategy Advisers held 651 positions worth $3.49B, up 36% from $2.57B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Weiss Multi-Strategy Advisers deployed $316M of net new capital in Q2 2020, opening 247 new positions and adding to 146 existing holdings. Its largest new stake was People Inc: 887,090 shares worth $51.3M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 26% a quarter earlier, followed by Industrials and Real Estate.

On the sell side, the largest reduction was Union Pacific, an estimated $43.1M trimmed.

  • Weiss Multi-Strategy Advisers's largest Q2 2020 buy was People Inc: 887,090 shares worth $51.3M.
  • Weiss Multi-Strategy Advisers added most to Qiagen in Q2 2020, an estimated $28.5M increase.
  • Weiss Multi-Strategy Advisers's biggest Q2 2020 reduction was Union Pacific, cutting an estimated $43.1M.
  • Weiss Multi-Strategy Advisers fully exited Allergan plc in Q2 2020, selling an estimated $78.6M.
  • Weiss Multi-Strategy Advisers's ten largest holdings make up 14% of its $3.49B portfolio in Q2 2020.
  • Weiss Multi-Strategy Advisers opened 247 new positions and closed 123 in Q2 2020.
  • Weiss Multi-Strategy Advisers's portfolio value rose 36% quarter-over-quarter to $3.49B.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2020, filed 14 Aug 2020.